Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk

Giuseppe Barbaro, Giorgio Barbarini

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The introduction of highly active antiretroviral therapy (HAART) has significantly modified the course of human immunodeficiency virus (HIV) disease, with longer survival and improved quality of life of HIV-infected subjects. However, HAART regimens, especially those including protease inhibitors, have been shown to cause in a high proportion of HIV-infected patients a metabolic syndrome (lipodystrophy/lipoatrophy, dyslipidemia, type 2 diabetes mellitus, insulin resistance) that may be associated with an increased risk of cardiovascular disease (coronary artery disease and stroke). A careful stratification of the cardiovascular risk and cardiovascular monitoring of patients under HAART is needed according to the most recent clinical guidelines.

Original languageEnglish
Pages (from-to)161-165
Number of pages5
JournalChemotherapy
Volume52
Issue number4
DOIs
Publication statusPublished - Jun 2006

Fingerprint

Metabolic Syndrome X
Highly Active Antiretroviral Therapy
HIV
Lipodystrophy
Physiologic Monitoring
Virus Diseases
Dyslipidemias
Protease Inhibitors
Type 2 Diabetes Mellitus
Insulin Resistance
Coronary Artery Disease
Cardiovascular Diseases
Stroke
Quality of Life
Guidelines
Survival

Keywords

  • Cardiovascular disease
  • Highly active antiretroviral therapy
  • Human immunodeficiency virus
  • Metabolic syndrome

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk. / Barbaro, Giuseppe; Barbarini, Giorgio.

In: Chemotherapy, Vol. 52, No. 4, 06.2006, p. 161-165.

Research output: Contribution to journalArticle

@article{7aafac9abf93417792ea7f7d524bacec,
title = "Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk",
abstract = "The introduction of highly active antiretroviral therapy (HAART) has significantly modified the course of human immunodeficiency virus (HIV) disease, with longer survival and improved quality of life of HIV-infected subjects. However, HAART regimens, especially those including protease inhibitors, have been shown to cause in a high proportion of HIV-infected patients a metabolic syndrome (lipodystrophy/lipoatrophy, dyslipidemia, type 2 diabetes mellitus, insulin resistance) that may be associated with an increased risk of cardiovascular disease (coronary artery disease and stroke). A careful stratification of the cardiovascular risk and cardiovascular monitoring of patients under HAART is needed according to the most recent clinical guidelines.",
keywords = "Cardiovascular disease, Highly active antiretroviral therapy, Human immunodeficiency virus, Metabolic syndrome",
author = "Giuseppe Barbaro and Giorgio Barbarini",
year = "2006",
month = "6",
doi = "10.1159/000093034",
language = "English",
volume = "52",
pages = "161--165",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk

AU - Barbaro, Giuseppe

AU - Barbarini, Giorgio

PY - 2006/6

Y1 - 2006/6

N2 - The introduction of highly active antiretroviral therapy (HAART) has significantly modified the course of human immunodeficiency virus (HIV) disease, with longer survival and improved quality of life of HIV-infected subjects. However, HAART regimens, especially those including protease inhibitors, have been shown to cause in a high proportion of HIV-infected patients a metabolic syndrome (lipodystrophy/lipoatrophy, dyslipidemia, type 2 diabetes mellitus, insulin resistance) that may be associated with an increased risk of cardiovascular disease (coronary artery disease and stroke). A careful stratification of the cardiovascular risk and cardiovascular monitoring of patients under HAART is needed according to the most recent clinical guidelines.

AB - The introduction of highly active antiretroviral therapy (HAART) has significantly modified the course of human immunodeficiency virus (HIV) disease, with longer survival and improved quality of life of HIV-infected subjects. However, HAART regimens, especially those including protease inhibitors, have been shown to cause in a high proportion of HIV-infected patients a metabolic syndrome (lipodystrophy/lipoatrophy, dyslipidemia, type 2 diabetes mellitus, insulin resistance) that may be associated with an increased risk of cardiovascular disease (coronary artery disease and stroke). A careful stratification of the cardiovascular risk and cardiovascular monitoring of patients under HAART is needed according to the most recent clinical guidelines.

KW - Cardiovascular disease

KW - Highly active antiretroviral therapy

KW - Human immunodeficiency virus

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=33745068786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745068786&partnerID=8YFLogxK

U2 - 10.1159/000093034

DO - 10.1159/000093034

M3 - Article

C2 - 16675900

AN - SCOPUS:33745068786

VL - 52

SP - 161

EP - 165

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 4

ER -